Research Nester assesses the growth of the Asia Pacific Alzheimer’s diagnosis and treatment market which is anticipated to be on account of the growing development of various drugs and diagnostics procedures followed by a rising count of people suffering from Alzheimer’s disease.
New York – February 16, 2023 - Research Nester’s recent market research analysis on “Asia Pacific Alzheimer’s Diagnosis and Treatment Market: Demand Analysis & Opportunity Outlook 2035” delivers a detailed competitors analysis and a detailed overview of the Asia Pacific Alzheimer’s diagnosis and treatment market in terms of market segmentation by treatment, treatment provider, diagnosis method, distribution channel, and by country.
Growing Cases of Alzheimer’s Affected People is to Drive Growth of Asia Pacific Alzheimer’s Diagnosis and Treatment Market
The Asia Pacific Alzheimer’s diagnosis and treatment market are estimated to grow majorly on account of the increasing cases of Alzheimer’s disease, and the growing population of old adults. The number of dementia patients in the Asia-Pacific region will triple by the year 2050. By the middle of the century, the Asia Pacific area will host more than half of the world's dementia patients. Moreover, the Asia-Pacific region's population is aging the quickest in the world, according to the United Nations. There are 630 million people living in the region, and about 60% of them are 60 or older. However, it is anticipated that by 2050, there will be 1.3 billion elderly people living in the region.
Some of the major growth factors and challenges that are associated with the growth of the Asia Pacific Alzheimer’s diagnosis and treatment market are:
- Surge in the Number of People Suffering from Alzheimer’s Disease
- Efforts put by Governmental Bodies to help the Patients
- Rising Approvals of New Development
- Investment Influx in the Healthcare Sector
- Growing Population Size of Elderly
The time-consuming procedure of drug development which makes it cost ineffective, the rise in the number of clinical trial failures, and the lack of public awareness are some of the major factors anticipated to hamper the growth of the Asia Pacific Alzheimer’s diagnosis and treatment market.
Access our detailed report at:
By diagnosis method, the Asia Pacific Alzheimer’s diagnosis and treatment market is segmented into CT scan, magnetic resonance (MRI), PET scans, electroencephalography (EEG), cerebrospinal fluid (CSF) test, and others. The PET scans segment is to garner the highest revenue of USD 898.8 million by the end of 2035 by growing at a CAGR of 9.5% over the projected time frame. Moreover, the segment is to garner a revenue of USD 333.8 million in 2022. The rise in the number of PET scanners installed in the region, and the high efficacy of PET scans in detecting dementia are a few factors that are likely to augment the segment growth.
By country, the China Alzheimer’s diagnosis and treatment market is to generate the highest revenue of USD 2004.8 million by the end of 2035 by growing at a CAGR of 14.8% over the forecast period. Moreover, the market in the region garnered a revenue of USD 474.0 million in 2022. This growth is anticipated by the higher number of people suffering from Alzheimer’s disease and the increasing population size of old adults.
This report also provides the existing competitive scenario of some of the key players of the Asia Pacific Alzheimer’s diagnosis and treatment market which includes company profiling of Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Lupin Pharmaceuticals, Inc., TauRx Therapeutics Ltd., Merz Pharma GmbH & Co. KGaA, AbbVie Inc., Siemens Healthcare Private Limited, Eli Lilly and Company, Biogen Inc., and Eisai Co., Ltd.